H.C. Wainwright downgraded Alpine Immune Sciences to Neutral from Buy with a $65 price target after the company entered a definitive agreement to be acquired by Vertex Pharmaceuticals (VRTX) for $4.9B or $65 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALPN: